EW - Edwards Lifesciences Corp
(NaN%)
SNP 500
Hold
Strong Growth but Declining
65%
based on last 5 year data.
Income Statement is MODERATE
Revenue Growth is 8.57%
Operating Income Growth is 5.33%
Net Income Growth is 197.68%
Earnings Per Share (EPS) Growth is 246.77%
Net Margin is 76.75%
Balance Sheet is STRONG
Current Asset to Current Liability Ratio is 4.18
Debt Ratio is 0.23
Current Debt to Net Income Ratio is 0.0
Total Debt to Total Assets Ratio is 0.05
Cash Flow is MODERATE
Cash from Operations Growth is -39.46%
Capital Expenditure is Low
Net Increase in Cash is Positive
Long Term Score Trend is NEGATIVE
Investment Risk is Low
based on last 4 quarter data.
Better viewed in landscape mode.
Period Ending | Revenue | Cost of Revenue | Gross Profit | Total Expense | Operating Expense | Operating Income | Operating Margin (%ge) | Net Other Income | Net Interest Income | Earnings Before Tax | Income Tax | Net Income | Net Margin (%ge) | Average Diluted (Shares Million) | EPS ($) | Dividend ($) | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FY 2024-12-31 | 5,439.50 | 1,117.50 | 4,322.00 | 4,060.80 | 2,943.30 | 1,378.70 | 25.35 | 169.40 | (19.80) | 1,548.10 | 152.10 | 4,174.60 | 76.75 | 599.30 | 6.97 | 0.00 | |
| FY 2023-12-31 | 5,010.00 | 978.40 | 4,031.60 | 3,701.10 | 2,722.70 | 1,308.90 | 26.13 | 63.50 | (17.60) | 1,372.40 | 152.40 | 1,402.40 | 27.99 | 2.70 | 2.01 | 0.00 | |
| FY 2022-12-31 | 4,464.00 | 723.70 | 3,740.30 | 2,965.60 | 2,241.90 | 1,498.40 | 33.57 | 21.10 | 16.30 | 1,519.50 | 195.50 | 1,521.90 | 34.09 | 5.20 | 2.12 | 0.00 | |
| FY 2021-12-31 | 7.30 | 1,248.90 | 3,983.60 | (1,683.00) | 2,293.30 | 1,690.30 | 23,154.79 | (9.40) | (1.00) | 1,702.00 | 198.90 | 1,503.10 | 20,590.41 | 631.20 | 2.38 | 0.00 | |
| FY 2020-12-31 | 4,386.30 | 1,080.60 | 3,305.70 | 3,488.70 | 2,408.10 | 897.60 | 20.46 | (17.70) | 7.60 | 916.70 | 93.30 | 823.40 | 18.77 | 631.90 | 1.30 | 0.00 | |
| FY 2019-12-31 | 4,348.00 | 1,114.40 | 3,233.60 | 1,439.70 | 2,086.80 | 1,146.80 | 26.38 | 8.20 | 11.50 | 1,166.50 | 119.60 | 1,046.90 | 24.08 | 636.70 | 1.64 | 0.00 | |
| FY 2018-12-31 | 3,722.80 | 939.40 | 2,783.40 | 1,058.10 | 2,035.20 | 748.20 | 20.10 | 4.00 | (29.90) | 1,522.80 | 39.20 | 722.20 | 19.40 | 640.90 | 1.13 | 0.00 | |
| FY 2017-12-31 | 3,435.30 | 875.30 | 2,560.00 | 903.50 | 1,470.60 | 1,089.40 | 31.71 | (1.40) | (2.90) | 2,069.80 | 451.30 | 583.60 | 16.99 | 647.70 | 0.90 | 0.00 | |
| FY 2016-12-31 | 2,963.70 | 797.40 | 2,166.30 | 821.60 | 1,415.10 | 751.20 | 25.35 | (4.90) | (8.40) | 1,475.80 | 168.40 | 569.50 | 19.22 | 653.40 | 0.87 | 0.00 | |
| FY 2015-12-31 | 2,493.70 | 617.20 | 1,876.50 | 711.30 | 94.10 | 1,782.40 | 71.48 | (4.00) | (9.30) | 1,244.80 | 127.50 | 494.90 | 19.85 | 660.90 | 0.75 | 0.00 | |
| FY 2014-12-31 | 2,322.90 | 625.60 | 1,697.30 | 659.20 | 33.60 | 1,663.70 | 71.62 | (7.70) | (10.80) | 2,288.00 | 332.90 | 811.10 | 34.92 | 651.00 | 1.25 | 0.00 | |
| FY 2013-12-31 | 2,045.50 | 516.60 | 1,528.90 | 568.50 | 51.90 | 1,477.00 | 72.21 | (6.70) | (5.20) | 1,022.40 | 122.10 | 389.10 | 19.02 | 682.80 | 0.57 | 0.00 | |
| FY 2012-12-31 | 1,899.60 | 491.00 | 1,408.60 | 524.70 | 33.70 | 1,374.90 | 72.38 | (3.20) | 0.40 | 776.40 | 96.70 | 291.50 | 15.35 | 709.80 | 0.41 | 0.00 |
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Edwards Lifesciences Corp (EW) - https://www.edwards.com
edwards lifesciences (nyse: ew) is the global leader in the science of heart valves and hemodynamic monitoring. driven by a passion to help patients, the company partners with clinicians to develop innovative technologies in the areas of structural heart disease and critical care monitoring that save and enhance lives. headquartered in irvine, california, edwards lifesciences has extensive operations in north america, europe, japan, latin america and asia and currently employs about 6,400 individuals worldwide. for us, helping patients is not a slogan – it's our life’s work. from developing devices that replace or repair a diseased heart valve to creating new technologies that monitor vital signs in the critical care setting, we help ensure that patients regain and even improve their quality of life.Exchange - NEW YORK STOCK EXCHANGE INC.
Industry - Surgical and Medical Instrument Manufacturing
Sector - Manufacturing
CEO - Michael Mussallem
Employees - 11,921
EW
Compare
Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2025 and future.
Know the Stock © 2025 and future.
We use cookies and other tracking technologies to improve experience and assess website traffic. By visiting our site, you acknowledge that you have read and understand the information in the below links and provide your consent to the same. Cookie Policy, Disclaimer, Privacy Policy, and Terms of Service